Sarepta Therapeutics (NASDAQ: SRPT) Climbs After Pfizer (NYSE: PFE) Study in DMD FailsPfizer Inc. (NYSE: PFE) today announced that CIFFREO ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE